A Phase II Trial of Evaluating Circulating Endothelial Cell as A Surrogate Marker for Monitoring Treatment Efficacy of Docetaxel Plus Capecitabine With Bevacizumab as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer.

Trial Profile

A Phase II Trial of Evaluating Circulating Endothelial Cell as A Surrogate Marker for Monitoring Treatment Efficacy of Docetaxel Plus Capecitabine With Bevacizumab as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Docetaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 07 Aug 2014 Status changed from active, no longer recruiting to discontinued as per the ClinicalTrials.gov record..
    • 15 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 23 Feb 2010 Status changed from active, no longer recruiting to recruiting as reported by Roche website.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top